focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Share News (REDX)

  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: FTSE 100 buoyed by UK manufacturing growth

Tue, 02nd Apr 2024 11:50

(Alliance News) - The FTSE 100 in London was up at midday on Tuesday, reacting to the UK manufacturing sector returning growth and further PMI data across the globe.

Oil majors and gold miners also soared in the FTSE 100 off the back of rising oil and bullion prices.

The FTSE 100 index was up 23.76 points, 0.3%, at 7,976.38. The FTSE 250 was down 58.37 points, 0.3%, at 19,826.36, and the AIM All-Share was up 0.40 of a point at 743.66.

The Cboe UK 100 was up 0.2% at 797.51, the Cboe UK 250 was down 0.7% at 17,220.34, and the Cboe Small Companies was up 0.2% at 14,590.74.

The UK manufacturing sector crossed the no-change mark into growth territory in March, according to the latest numbers from S&P Global.

The seasonally adjusted S&P Global UK manufacturing purchasing managers' index reading was 50.3 points in March, up from 47.5 in February and beating the earlier flash estimate of 49.9.

The latest figure was above the 50-point no-change mark, meaning the UK manufacturing sector returned to growth territory.

Pantheon Macroeconomics analyst Rob Wood commented: "The long downturn in manufacturing output is over according to the PMI...This isn't just a flash in the pan, with the forward-looking indications from the PMI suggesting growth will improve further.

"Expectations for growth in output over the next 12 months also improved to 75.9 in March from 73.5 in February, above their average level of 72.4 since this question was first asked in 2012 and the highest since April 2023."

UK house prices rose 1.6% in March compared to a year ago, according to the latest Nationwide survey and coming in below FXStreet-cited expectations of a 2.4% rise. In February, this rose by 1.2%.

On a monthly basis, prices fell 0.2% in March from February, compared to a 0.7% rise in February from January. The market expected a 0.3% rise.

"The UK housing market has been doing its best to bounce back, yet latest data from Nationwide would suggest it is still a slog to shift property," said AJ Bell analyst Russ Mould.

"House price growth was subdued in March as many people remain priced out of the market. We really need to see interest rate cuts to prompt a big drop in mortgage rates and improve affordability levels."

Market attention was otherwise dominated by the release of manufacturing PMI data, with more to come on Tuesday.

Growth in the US manufacturing sector continued in March but at a slower rate, final purchasing managers' index survey results from S&P Global confirmed on Monday, while the similar Institute for Supply Management survey showed a swing to growth from contraction.

The S&P Global US manufacturing PMI slipped to 51.9 points in March from 52.2 in February. This was below the flash result for March, released last month, which had shown an improvement to 52.5 points.

The score for last month was still above the neutral 50-point mark, and the expansion in production reached a 22-month-high.

The ISM PMI showed a more striking improvement last month, indicating a swing to expansion from contraction.

The ISM PMI for manufacturing reading was 50.3 points for March, compared to 47.8 for February and 49.1 for January. A less impressive rise to 48.4 points was expected for last month.

The readings came after data showed US inflation pressure eased ever-so-slightly in February to 2.8% on-year from 2.9% in January, according to the Federal Reserve's preferred indicator, the core personal consumption expenditures index. The data, released on Friday, was in line with consensus cited by FXStreet.

The core data excludes food and energy. The annual headline PCE index, which does not, picked up 2.5% in February, accelerating slightly from 2.4% in January. The February outcome was in line with consensus.

Stocks in New York were called lower. The Dow Jones Industrial Average was called down 0.3%, while the S&P 500 index and the Nasdaq Composite were both called down 0.2%.

Meanwhile, the eurozone's manufacturing sector sunk to a three-month low in March, numbers on Tuesday showed, though there were "signs of positive momentum building".

The latest Hamburg Commercial Bank manufacturing purchasing managers' index fell to 46.1 points in March, from 46.5 in February. The latest reading was a three-month low, but topped the flash estimate of 45.7 points.

Germany's manufacturing sector remained "firmly in contraction" in March, according to data from the Hamburg Commercial Bank on Tuesday.

The manufacturing purchasing managers' index for Germany registered 41.9 points in March, down from 42.5 points in February and further below the 50 point no-change mark.

A score of 50.0 separates expansion from decline.

In European equities on Tuesday, the CAC 40 in Paris was marginally down, while the DAX 40 in Frankfurt was down 0.2%.

The pound fell to USD1.2564 on Tuesday midday in London, compared to USD1.2640 at the equities close on Thursday last week. The euro stood lower at USD1.0741, against USD1.0803. Against the yen, the dollar was trading higher at JPY151.69 on Tuesday, compared to JPY151.29 late Thursday.

In London's FTSE 100, gold miners and oil majors were among the better large-cap performers.

Fresnillo and Anglo American traded 7.1% and 4.0% higher respectively, while Shell and BP rose 3.2% and 2.9% respectively.

Brent oil rose steeply to USD88.95 a barrel at midday in London on Tuesday from USD86.56 late Thursday last week. Gold rose to USD2,260.27 an ounce against USD2,221.01.

HSBC rose 1.0%, after it announced it sealed the sale of HSBC Bank Canada to Royal Bank of Canada.

The lender will book a USD4.9 billion "estimated gain on sale" in its first quarter, inclusive of the recycling of an estimated USD600 million in foreign currency translation reserve losses.

HSBC intends to declare a special dividend of USD0.21 per share in its first quarter earnings, subject to board approval and finalisation of results. This would be in addition to any proposed interim dividend and payable at the same time in June if approved.

AstraZeneca ticked down 0.1%.

The pharmaceutical firm said its biologics licence application for datapotamab deruxtecan was accepted by the US Food & Drug Administration for the treatment of specific forms of breast cancer.

AstraZeneca said the decision was based on the results of the Tropion-Breast01 phase 3 trial in which Dato-DXd "demonstrated a statistically significant and clinically meaningful improvement" in progression-free survival compared to chemotherapy and at least one systemic therapy.

The prescription drug user fee act date, the FDA action date for its regulatory decision, is during the first quarter of 2025.

Meanwhile, AstraZeneca's Voydeya has been approved in the US to treat extravascular haemolysis in adults suffering from rare blood disease paroxysmal nocturnal haemoglobinuria. The FDA approval comes off the back of positive results from the Alpha phase 3 trial.

In the FTSE 250, Hochschild Mining rose 2.6%, after the gold and silver miner sold its Crespo project in southern Peru for USD15 million to Kina Mining Peru.

Among London's small-caps, CMC Markets rose 3.9% to 226 pence, after RBC raised its price target for the online trading firm to 240p from 190p, rating the stock at 'outperform'.

On Wednesday last week, CMC Markets raised its full-year outlook after a positive fourth quarter.

In a trading update for the financial year ending March, the London-based online trading firm said it expects full-year net operating income to exceed the top end of the previously guided range of between GBP290 million and GBP310 million. This would be up from GBP288.4 million in financial 2023.

On AIM in London, Redx Pharma lost 59%, after it said intends to cancel its shares from trading on AIM in London, subject to shareholder approval.

The clinical-stage biotechnology company said the board unanimously concluded that it is in the best interests of the company to re-register as a private limited company, as it is "still liquidity constrained" on AIM.

A general meeting has been called for April 19 for Redx Pharma shareholders to vote on the cancellation resolution.

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
17 May 2023 14:44

Redx Pharma half-year loss doubles amid costs of failed Jounce merger

(Alliance News) - Redx Pharma PLC on Wednesday said its half-year loss nearly doubled, due to lower revenue and higher expenses, but it noted progress in therapeutics trials and said it "retains the foundations for longer term success".

Read more
11 May 2023 18:17

IN BRIEF: Redx reports positive preclinical data for fibrosis drug

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company - Announces preclinical data for its lead fibrosis asset, RXC007, and the Discodin Domain Receptor 1/2 discovery programme, as presented yesterday at the Resistant Tumour Microenvironment, Keystone Symposia, in Vancouver. Notes the data presented were from preclinical models of pancreatic ductal adenocarcinoma and triple negative breast cancer in combination with chemotherapy and immunotherapy, as current standard of care. Says RXC007, in combination with gemcitabine/Abraxane in metastatic and high-extra cellular matrix patient-derived PDAC models, was shown to increase survival compared to single agent standard of care alone. The combination of RXC007 with standard of care provided a significant increase in median survival days from date of treatment in a dose dependent manner. These new data on RXC007 complement those also presented at the meeting by collaboration partner the Garvan Institute of Medical Research on REDX10616, a close analogue of RXC007. Taken together, these data provide a strong rationale for the potential of ROCK2 inhibition in combination with standard of care as a potential treatment for cancer-associated fibrosis. Redx plans to further investigate this treatment setting with the company's next-generation ROCK2 inhibitor, RXC007. Further, at the Keystone Symposia, data were also presented from Redx's DDR1/2 programme in combination with anti-PD-1 in TNBC models. Using a tool DDR1/2 inhibitor, in combination with anti-PD-1, in the TNBC E0771 model resulted in a statistically significant increase in survival when compared to the control group, an effect not observed with either single agent alone.

Read more
10 May 2023 15:45

UK earnings, trading statements calendar - next 7 days

Thursday 11 May 
3i Group PLCFull Year Results
Airtel Africa PLCFull Year Results
Eurocell PLCTrading Statement
Donegal Investment Group PLCHalf Year Results
Grainger PLCHalf Year Results
Hurricane Energy PLCFull Year Results
ICG Enterprise Trust PLCFull Year Results
IQE PLCFull Year Results
ITV PLCTrading Statement
John Wood Group PLCTrading Statement
Morgan Advanced Materials PLCTrading Statement
Rolls-Royce Holdings PLCTrading Statement
S4 Capital PLCQ1 Results
TBC Bank Group PLCQ1 Results
Friday 12 May 
Allianz Technology Trust PLCQ1 Results
Balfour Beatty PLCTrading Statement
Beazley PLCQ1 Results
CMO Group PLCFull Year Results
Monday 15 May 
CentralNic Group PLCFull Year Results
Cerillion PLCHalf Year Results
Currys PLCTrading Statement
Diploma PLCHalf Year Results
Equals Group PLCTrading Statement
Finsbury Growth & Income Trust PLCHalf Year Results
Instem PLCFull Year Results
JPMorgan Multi-Asset Growth & Income PLCFull Year Results
Westminster Group PLCFull Year Results
Tuesday 16 May 
Angling Direct PLCFull Year Results
boohoo Group PLCFull Year Results
Britvic PLCHalf Year Results
Burford Capital LtdFull Year Results
Cornerstone FS PLCFull Year Results
DCC PLCFull Year Results
Essentra PLCTrading Statement
Greggs PLCTrading Statement
Hyve Group PLCHalf Year Results
Imperial Brands PLCHalf Year Results
Land Securities Group PLCFull Year Results
Likewise Group PLCFull Year Results
Marston's PLCHalf Year Results
Renew Holdings PLCHalf Year Results
Smartspace Software PLCFull Year Results
Vodafone Group PLCFull Year Results
Zytronic PLCHalf Year Results
Wednesday 17 May 
Auction Technology Group PLCHalf Year Results
Bank of Georgia Group PLCQ1 Results
British Land Co PLCFull Year Results
Experian PLCFull Year Results
JD Sports Fashion PLCFull Year Results
Keller Group PLCTrading Statement
Ninety One PLC and LtdFull Year Results
Redx Pharma PLCHalf Year Results
Sage Group PLCHalf Year Results
Scottish Mortgage Investment Trust PLCFull Year Results
TP ICAP Group PLCQ1 Results
Watches of Switzerland Group PLCTrading Statement
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
3 Apr 2023 18:05

TRADING UPDATES: Redx confirms Jounce deal lapses, Tirupati seals deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
27 Mar 2023 14:34

Redx Pharma's bid to buy Jounce snubbed by Concentra's higher offer

(Alliance News) - Redx Pharma PLC on Monday noted that Jounce Therapeutics Inc, which it was close to buying, was bought by Concentra Biosciences LLC for a higher price.

Read more
27 Mar 2023 14:16

Jounce agrees Concentra Bioscences takeover, ditches Redx Pharma

(Sharecast News) - Jounce Therapeutics said on Monday that it was ditching a planned merger with AIM-listed Redx Pharma, opting instead to be bought by Concentra Bioscences.

Read more
8 Mar 2023 12:07

LONDON MARKET MIDDAY: Stocks down, pound below USD1.19 on US rate view

(Alliance News) - Stock prices in London were lower at midday on Wednesday, with investors still reeling from surprisingly hawkish comments by US Federal Reserve Chair Jerome Powell on Tuesday.

Read more
8 Mar 2023 11:52

Redx Pharma shares slide on RXC004 monotherapy blow

(Alliance News) - Redx Pharma PLC on Wednesday said first results of its phase 2 programme indicate were not sufficient enough to support the development of its RXC004 treatment as a monotherapy.

Read more
8 Mar 2023 10:42

AIM WINNERS & LOSERS: Redx drops on disappointing cancer drug results

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
7 Mar 2023 15:44

UK shareholder meetings calendar - next 7 days

Wednesday 8 March 
Amigo Holdings PLCGM re the company's capital position
boohoo Group PLCGM re adoption of the Growth Plan
Creo Medical Group PLCGM re open offer shares
Globalworth Real Estate Investments LtdEGM re grant options and script dividends
Henderson Opportunities Trust PLCAGM
Jersey Electricity PLCAGM
Thursday 9 March 
CT Capital & Income Investment Trust PLCAGM
Shoe Zone PLCAGM
WAG Payment Solutions PLCGM re proposed acquisition of Inelo
Friday 10 March 
Atrato Onsite Energy PLCAGM
Malin Corp PLCAGM
Mineral & Financial Investments LtdAGM
Monday 13 March 
BlackRock Energy & Resources Income Trust PLCAGM
Hercules Site Services PLCAGM
Hummingbird Resources PLCGM re strategic investment and placement
Ironveld PLCGM re second placing shares on AIM
Tuesday 14 March 
Georgia Capital PLCGM re company's transfer from Premium to Standard listing
MTI Wireless Edge LtdAGM
Redx Pharma PLCAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
23 Feb 2023 10:24

Redx Pharma and Jounce Therapeutics agree transatlantic merger

(Alliance News) - Redx Pharma PLC and Jounce Therapeutics Inc on Thursday said they have agreed to an all-share merger that will create a USD425 million company focused on the treatment of cancer and fibrotic diseases.

Read more
23 Feb 2023 07:56

LONDON BRIEFING: WPP profit jumps in 2022; guides for further growth

(Alliance News) - Stocks in London were called to open slightly higher on Thursday, as investors were unfazed by a fairly uneventful set of policy meeting minutes from the US central bank.

Read more
9 Feb 2023 12:25

IN BRIEF: Redx Pharma makes progress on fibrosis candidate study

Redx Pharma PLC - Alderley Edge, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - Updates on its lead fibrosis candidate, RXC007, which is currently being assessed in a phase 2a study. Says regulatory and ethics approvals for the 28-day and 12-week cohorts of the study have been received in five countries. Adds recruitment is progressing at a number of study sites, but says enrolment in the US 12-week cohort has not begun due to a partial US Food & Drug Adminstration hold, pending a data readout from an ongoing non-clinical programme. The requested data is expected later this year. US enrolment in the 28-day cohort is unaffected.

Read more
20 Dec 2022 14:29

EARNINGS SUMMARY: Goodwin achieves rise in interim profit and revenue

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
16 Dec 2022 21:22

TRADING UPDATES: Uniphar takeover fails; Pearson notes redemption end

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.